SN Compr Clin Med. 2020 Sep 10:1-5. doi: 10.1007/s42399-020-00510-x. Online ahead of print.
ABSTRACT
With many drugs being tried in the management and treatment of COVID-19, dupilumab is one such monoclonal antibody that has come under the limelight for its possible role as an adjunct therapy in COVID-19 position. There are isolated case reports and series that document a milder course of COVID-19 infection in patients who have already been on dupilumab therapy for treatment of conditions such as atopic dermatitis and chronic rhino-sinusitis with nasal polyp. There is also an ongoing debate regarding the continuation of biologicals in the COVID patient. In this article, a non-systematic critical analysis of dupilumab was performed to delve into this hypothesis further.
PMID:32935079 | PMC:PMC7483051 | DOI:10.1007/s42399-020-00510-x